Aw, Tar-Ching Blair, Iain and Babcock, Hilary M. 2017. Infectious Diseases.
Barrette, Ernie-Paul Escota, Gerome V. and Patel, Rupa 2017. Infectious Diseases.
Carrion, Malwina N. and Hamer, Davidson H. 2017. International Encyclopedia of Public Health.
Cheng, Vincent Chi-Chung Chan, Jasper Fuk-Woo Hung, Ivan Fan-Ngai and Yuen, Kwok-Yung 2017. International Encyclopedia of Public Health.
Delaney, Kevin P. Hanson, Debra L. Masciotra, Silvina Ethridge, Steven F. Wesolowski, Laura and Owen, Sherry Michele 2017. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clinical Infectious Diseases, Vol. 64, Issue. 1, p. 53.
Taplitz, Randy A. Ritter, Michele L. and Torriani, Francesca J. 2017. Infectious Diseases.
Berenji, Manijeh 2016. Physical and Biological Hazards of the Workplace.
Brett-Major, D. M. Scott, P. T. Crowell, T. A. Polyak, C. S. Modjarrad, K. Robb, M. L. and Blazes, D. L. 2016. Are you PEPped and PrEPped for travel? Risk mitigation of HIV infection for travelers. Tropical Diseases, Travel Medicine and Vaccines, Vol. 2, Issue. 1,
Chi-Chung Cheng, Vincent Fuk-Woo Chan, Jasper FN Hung, Ivan and Yuen, Kwok-Yung 2016. Reference Module in Biomedical Sciences.
Choi, Jun Yong 2016. Updates on Preventing HIV Infection. The Korean Journal of Medicine, Vol. 90, Issue. 6, p. 474.
Cleveland, Jennifer L. Gray, Shellie Kolavic Harte, Jennifer A. Robison, Valerie A. Moorman, Anne C. and Gooch, Barbara F. 2016. Transmission of blood-borne pathogens in US dental health care settings. The Journal of the American Dental Association, Vol. 147, Issue. 9, p. 729.
Díaz, Juan C. and Johnson, Lucas A. 2016. Health care worker follow-up compliance after occupational bloodborne pathogens exposure: A brief report. American Journal of Infection Control, Vol. 44, Issue. 12, p. 1738.
Fätkenheuer, G Jessen, H Stoehr, A Jung, N Jessen, AB Kümmerle, T Berger, M Bogner, JR Spinner, CD Stephan, C Degen, O Vogelmann, R Spornraft-Ragaller, P Schnaitmann, E Jensen, B Ulmer, A Kittner, JM Härter, G Malfertheiner, P Rockstroh, J Knecht, G Scholten, S Harrer, T Kern, WV Salzberger, B Schürmann, D and Ranneberg, B 2016. PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis. HIV Medicine, Vol. 17, Issue. 6, p. 453.
Henderson, Duncan Sims-Williams, Hugh P. Wilhelm, Thomas Sims-Williams, Helen Bhagani, Sanjay and Thorne, Lewis 2016. Neurosurgery and human immunodeficiency virus in the era of combination antiretroviral therapy: a review. Journal of Neurosurgery, p. 1.
Hughes, Heather Y. and Henderson, David K. 2016. Postexposure prophylaxis after hepatitis C occupational exposure in the interferon-free era. Current Opinion in Infectious Diseases, Vol. 29, Issue. 4, p. 373.
Kalapila, Aley G. and Marrazzo, Jeanne 2016. Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. Medical Clinics of North America, Vol. 100, Issue. 4, p. 927.
Kassa, Getachew Selenic, Dejana Lahuerta, Maria Gaolathe, Tendani Liu, Yang Letang, Garegole Courtenay-Quirk, Cari Mwaniki, Nelson Kiama Gaolekwe, Sarah and Bock, Naomi 2016. Occupational exposure to bloodborne pathogens among health care workers in Botswana: Reporting and utilization of postexposure prophylaxis. American Journal of Infection Control, Vol. 44, Issue. 8, p. 879.
Leal, Lorna León, Agathe Torres, Berta Inciarte, Alexy Lucero, Constanza Mallolas, Josep Laguno, Montserrat Martínez-Rebollar, María González-Cordón, Ana Manzardo, Christian Rojas, Jhon Pich, Judit Arnaiz, Joan A. Gatell, Josep M. and García, Felipe 2016. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy, Vol. 71, Issue. 7, p. 1987.
Lin, SY Lachowsky, NJ Hull, M Rich, A Cui, Z Sereda, P Jollimore, J Stephenson, K Thumath, M Montaner, JSG Roth, EA Hogg, RS and Moore, DM 2016. Awareness and use of nonoccupational post-exposure prophylaxis among men who have sex with men in Vancouver, Canada. HIV Medicine, Vol. 17, Issue. 9, p. 662.
Lori, Jody R. McCullagh, Marjorie C. Krueger, Alicia and Oteng, Rockefeller 2016. Sharps injuries among emergency department nurses in one tertiary care hospital in Ghana. International Emergency Nursing, Vol. 28, p. 14.
This report updates US Public Health Service recommendations for the management of healthcare personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management remain unchanged, recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated. This report emphasizes the importance of primary prevention strategies, the prompt reporting and management of occupational exposures, adherence to recommended HIV PEP regimens when indicated for an exposure, expert consultation in management of exposures, follow-up of exposed HCP to improve adherence to PEP, and careful monitoring for adverse events related to treatment, as well as for virologie, immunologic, and serologic signs of infection. To ensure timely postexposure management and administration of HIV PEP, clinicians should consider occupational exposures as urgent medical concerns, and institutions should take steps to ensure that staff are aware of both the importance of and the institutional mechanisms available for reporting and seeking care for such exposures. The following is a summary of recommendations: (1) PEP is recommended when occupational exposures to HIV occur; (2) the HIV status of the exposure source patient should be determined, if possible, to guide need for HIV PEP; (3) PEP medication regimens should be started as soon as possible after occupational exposure to HIV, and they should be continued for a 4-week duration; (4) new recommendation—PEP medication regimens should contain 3 (or more) antiretroviral drugs (listed in Appendix A) for all occupational exposures to HIV; (5) expert consultation is recommended for any occupational exposures to HIV and at a minimum for situations described in Box 1; (6) close follow-up for exposed personnel (Box 2) should be provided that includes counseling, baseline and follow-up HIV testing, and monitoring for drug toxicity; follow-up appointments should begin within 72 hours of an HIV exposure; and (7) new recommendation—if a newer fourth-generation combination HIV p24 antigen-HIV antibody test is utilized for follow-up HIV testing of exposed HCP, HIV testing may be concluded 4 months after exposure (Box 2); if a newer testing platform is not available, follow-up HIV testing is typically concluded 6 months after an HIV exposure.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
Abstract views reflect the number of visits to the article landing page.
* Views captured on Cambridge Core between September 2016 - 21st August 2017. This data will be updated every 24 hours.